IMMUNOTHERAPY AGAINST SEVERAL TUMORS, SUCH AS LUNG CANCER, INCLUDING NSCLC
First Claim
1. A method of treating a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, gastric cancer, and/or glioblastoma, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide, wherein said peptide comprises an amino acid sequence of KIQEMQHFL (SEQ ID NO:
- 2), wherein the peptide is in a complex with an MHC molecule.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of treating a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma. A method of treating a patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the NSCLC, lung cancer, gastric cancer, and/or glioblastoma.
-
Citations
20 Claims
-
1. A method of treating a patient who has non-small cell lung carcinoma (NSCLC), lung cancer, gastric cancer, and/or glioblastoma, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide, wherein said peptide comprises an amino acid sequence of KIQEMQHFL (SEQ ID NO:
- 2), wherein the peptide is in a complex with an MHC molecule.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
14. A pharmaceutical composition comprising activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, wherein said peptide consists of an amino acid sequence of KIQEMQHFL (SEQ ID NO:
- 2), and a pharmaceutically acceptable carrier, wherein the T cells bind to the peptide in a complex with an MHC class I molecule, and wherein the composition is for treating the patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma.
- View Dependent Claims (15, 16, 17, 18)
-
19. A method of treating a patient who has NSCLC, lung cancer, gastric cancer, and/or glioblastoma, comprising administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, wherein said peptide comprises an amino acid sequence of KIQEMQHFL (SEQ ID NO:
- 2), thereby inducing a T-cell response to the NSCLC, lung cancer, gastric cancer, and/or glioblastoma.
- View Dependent Claims (20)
Specification